Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 17;17(1):38.
doi: 10.1186/s12985-020-01311-3.

Prevalence of acquired drug resistance mutations in antiretroviral- experiencing subjects from 2012 to 2017 in Hunan Province of central South China

Xiaobai Zou  1 , Jianmei He  1 , Jun Zheng  1 , Roberta Malmgren  2 , Weisi Li  3 , Xiuqing Wei  1 , Guoqiang Zhang  1 , Xi Chen  4
Affiliations

Prevalence of acquired drug resistance mutations in antiretroviral- experiencing subjects from 2012 to 2017 in Hunan Province of central South China

Xiaobai Zou et al. Virol J. .

Abstract

Background: There are few data on the prevalence of acquired drug resistance mutations (ADRs) in Hunan Province, China, that could affect the effectiveness of antiretroviral therapy (ART).

Objectives: The main objectives of this study were to determine the prevalence of acquired drug resistance (ADR) the epidemic characteristics of HIV-1-resistant strains among ART-failed HIV patients in Hunan Province, China.

Methods: ART-experienced and virus suppression failure subjects in Hunan between 2012 and 2017 were evaluated by genotyping analysis and mutations were scored using the HIVdb.stanford.edu algorithm to infer drug susceptibility.

Results: The prevalence of HIV-1 ADR were 2.76, 2.30, 2.98, 2.62, 2.23and 2.17%, respectively, from 2012 to 2017. Overall 2295 sequences were completed from 2932 ART-failure patients, and 914 of these sequences were found to have drug resistance mutation. The most common subtype was AE (64.14%), followed by BC (17.91%) and B (11.50%). Among those 914 patients with drug resistance mutations,93.11% had NNRTI-associated drug resistance mutations, 74.40% had NRTI drug resistance mutations (DRMs) and 6.89% had PI DRMs. Dual-class mutations were observed in 591 (64.66%) cases, and triple-class mutations were observed in 43 (4.70%) cases. M184V (62.04%), K103N (41.90%) and I54L (3.83%) were the most common observed mutations, respectively, in NRTI-, NNRTI- and PI-associated drug resistance. 93.76% subjects who had DRMs received the ART first-line regimens. CD4 count, symptoms in the past 3 months, and ART adherence were found to be associated with HIV-1 DR.

Conclusions: This study showed that although the prevalence of HIV-acquired resistance in Hunan Province is at a low-level, the long-term and continuous surveillance of HIV ADR in antiretroviral drugs (ARVs) patients is necessary.

Keywords: Acquired drug resistance; China; HIV; Mutation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Aldous AM, Castel AD, Parenti DM. Prevalence and trends in transmitted and acquired antiretroviral drug resistance, Washington, DC, 1999-2014. BMC Res Notes. 2017;10:474. doi: 10.1186/s13104-017-2764-9. - DOI - PMC - PubMed
    1. Miller V, Phillips A, Rottmann C, Staszewski S, Pauwels R, et al. Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure. J Infect Dis. 1998;177:1521–1532. doi: 10.1086/515304. - DOI - PubMed
    1. Zhang F, Liu L, Sun M, Sun J, Lu H. An analysis of drug resistance among people living with HIV/AIDS in Shanghai, China. PLoS One. 2017;12:e165110. - PMC - PubMed
    1. Ndahimana J, Riedel DJ, Mwumvaneza M, Sebuhoro D, Uwimbabazi JC, et al. Drug resistance mutations after the first 12 months on antiretroviral therapy and determinants of virological failure in Rwanda. Tropical Med Int Health. 2016;21:928–935. doi: 10.1111/tmi.12717. - DOI - PubMed
    1. Stadeli KM, Richman DD. Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther. 2013;18:115–123. doi: 10.3851/IMP2437. - DOI - PMC - PubMed

Publication types

Substances